208 related articles for article (PubMed ID: 32144278)
1. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.
Sagers JE; Beauchamp RL; Zhang Y; Vasilijic S; Wu L; DeSouza P; Seist R; Zhou W; Xu L; Ramesh V; Stankovic KM
Sci Rep; 2020 Mar; 10(1):4211. PubMed ID: 32144278
[TBL] [Abstract][Full Text] [Related]
2. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
[TBL] [Abstract][Full Text] [Related]
3. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
[TBL] [Abstract][Full Text] [Related]
4. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V
Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339
[TBL] [Abstract][Full Text] [Related]
5. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
6. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
[TBL] [Abstract][Full Text] [Related]
7. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
8. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
[TBL] [Abstract][Full Text] [Related]
9. Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells.
Hardin HM; Dinh CT; Huegel J; Petrilli AM; Bracho O; Allaf AM; Karajannis MA; Griswold AJ; Ivan ME; Morcos J; Gultekin SH; Telischi FF; Liu XZ; Fernandez-Valle C
Mol Cancer Ther; 2023 Nov; 22(11):1280-1289. PubMed ID: 37527526
[TBL] [Abstract][Full Text] [Related]
10. Combined mTOR/MEK inhibition prevents proliferation and induces apoptosis in NF2-mutant tumors.
Li N; Lu XY; Shi WY; Mao FJ; Yang XY; Luo YB; Li W
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5874-5883. PubMed ID: 31298338
[TBL] [Abstract][Full Text] [Related]
11. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
Agnihotri S; Gugel I; Remke M; Bornemann A; Pantazis G; Mack SC; Shih D; Singh SK; Sabha N; Taylor MD; Tatagiba M; Zadeh G; Krischek B
J Neurosurg; 2014 Dec; 121(6):1434-45. PubMed ID: 25245477
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia.
Hadley G; Beard DJ; Alexopoulou Z; Sutherland BA; Buchan AM
Neurosci Lett; 2019 Jul; 706():223-230. PubMed ID: 31100427
[TBL] [Abstract][Full Text] [Related]
13. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
14. Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
Pi R; Yang Y; Hu X; Li H; Shi H; Liu Y; Wang X; Tong A; Lu T; Wei Y; Zhao X; Wei X
Cancer Lett; 2021 Dec; 523():72-81. PubMed ID: 34560229
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS
Eur J Cancer; 2009 Jun; 45(9):1709-20. PubMed ID: 19359162
[TBL] [Abstract][Full Text] [Related]
16. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
Fuse MA; Plati SK; Burns SS; Dinh CT; Bracho O; Yan D; Mittal R; Shen R; Soulakova JN; Copik AJ; Liu XZ; Telischi FF; Chang LS; Franco MC; Fernandez-Valle C
Mol Cancer Ther; 2017 Nov; 16(11):2387-2398. PubMed ID: 28775147
[TBL] [Abstract][Full Text] [Related]
18. Directly imaging the localisation and photosensitization properties of the pan-mTOR inhibitor, AZD2014, in living cancer cells.
Ahmed AR; Candeo A; D'Abrantes S; Needham SR; Yadav RB; Botchway SW; Parker AW
J Photochem Photobiol B; 2020 Dec; 213():112055. PubMed ID: 33142217
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells.
Sabha N; Au K; Agnihotri S; Singh S; Mangat R; Guha A; Zadeh G
PLoS One; 2012; 7(6):e39412. PubMed ID: 22745749
[TBL] [Abstract][Full Text] [Related]
20. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.
Bhattacharyya S; Oblinger JL; Beauchamp RL; Yin Z; Erdin S; Koundinya P; Ware AD; Ferrer M; Jordan JT; Plotkin SR; Xu L; Chang LS; Ramesh V
Neuro Oncol; 2023 Sep; 25(9):1617-1630. PubMed ID: 36806881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
